LABORATORY STUDY

Potential role of estradiol in ovariectomy-induced derangement of renal endocrine functions

Ahmed A. El-Gendya, Wael M. Elsaedc,d and Hesham I. Abdallahc,e

aDepartment of Medical Physiology, Faculty of Medicine, Taibah University, Madinah, Saudi Arabia; bDepartment of Medical Physiology, Faculty of Medicine, Mansoura University, Mansoura, Egypt; cDepartment of Anatomy & Embryology, Faculty of Medicine, Taibah University, Madinah, Saudi Arabia; dDepartment of Anatomy & Embryology, Faculty of Medicine, Mansoura University, Mansoura, Egypt; eDepartment of Anatomy & Embryology, Faculty of Medicine, Ain Shams University, Cairo, Egypt

ABSTRACT
Menopause is an important physiological event associated with structural and functional changes in the kidneys. An animal model of bilateral ovariectomy was used to study the effects of estrogen depletion, replacement and antiestrogen on renal structure and endocrine function. Sixty female rats were divided into six groups; group I was the control group, the remaining five groups underwent ovariectomy: group II received no treatment. The other groups received estradiol in group III, tamoxifen in group IV, estradiol followed by tamoxifen in group V and tamoxifen followed by estradiol in group VI. Serum creatinine, blood urea nitrogen, and endocrine functions of kidney were measured. Tissue samples were examined both microscopically for beta estrogen receptors and ultrastructurally for cell changes. Groups II, IV & VI showed a significant increase in creatinine, blood urea nitrogen, renal malondialdehyde, renal erythropoietin, plasma renin and plasma prostaglandin E2 and a significant decrease in renal antioxidants and serum vitamin D3. Groups III & V had a significant decrease in creatinine, blood urea nitrogen, renal malondialdehyde and renal erythropoietin with an increase in renal antioxidants, plasma prostaglandin E2 and serum vitamin D3. Histopathological and ultrastructural examinations revealed atrophic tubular changes in group II. The changes were less marked in groups III & V and more extensive in groups IV & VI. Estrogen receptor beta staining showed progressively increased expression in the absence of estrogen. Structural and most endocrine functions of the kidney were significantly affected by estradiol deficiency. Estradiol replacement exhibited a protective effect on renal tissue and endocrine functions.

ARTICLE HISTORY
Received 31 December 2018
Revised 23 May 2019
Accepted 24 May 2019

KEYWORDS
Ovariectomy; estradiol; tamoxifen; renal endocrine; ER-β

Introduction
Besides the excretory role of the kidney, it has various endocrine functions some of which are still being discovered and elucidated [1]. Several hormones with different functions are secreted by the kidneys. Renin, for example, is released from the juxtaglomerular cells and has autocrine and paracrine effects [2]. Angiotensin-converting enzyme presents in abundance in the proximal tubule (PT) brush border, apart from other sites in the renal tissue [3]. Erythropoietin (EPO) is produced in the interstitial cells of the renal cortex near the bases of the PT and peritubular cells in response to the sensing of oxygen deficiency [4]. In addition, the active forms of vitamin D (vitamin D3) is synthesized in the mitochondria of the PT [5,6]. Furthermore, the renal tissue is involved in the production of adrenomedullin, endothelins, and prostaglandins [7]. Prostaglandin E2 is an important physiologic regulator of blood flow and electrolytes and water homeostasis in the kidney [8]. Prostaglandin E2 is synthesized by cyclooxygenases; COX-1 and COX-2 which stimulate the formation of prostaglandins from arachidonic acid [9].

The kidney also plays an important role in inflammatory cytokines production and regulation through the control of renin-angiotensin system (RAS) cascade [10]. At the same time, kidneys are targeted by various hormones to regulate their functions especially sex hormones [11]. Estradiol (E2) is essential for the normal cellular growth and differentiation, maintenance of the kidney functions [12] and regulation of the renal homeostatic activities [13]. The disturbance in serum E2 level is supposed to affect the morphology and functions of the kidneys. The incidence of kidney diseases, for instance, is known to be gender-related [14].
Estradiol has a protective role against the progression of chronic renal diseases [15]. While decreased synthesis of E2 makes the kidney more vulnerable to renal oxidative injuries [16]. On the other hand, it has been observed that the E2 replacement therapy modifies renal dysfunction and inhibits ultrastructural deterioration after bilateral ovariectomy (OVX) [17,18].

Ovariectomy in experimental animals is a considerable model of studying the effects of E2 deficiency in menopause [19]. Removal of the ovaries accelerates the progression of the renal pathological changes, increases the oxidative stress by the high production of reactive oxygen species (ROS), and disturbs the renal functions involving endocrines [20].

Estradiol mediates its bioeffect by binding to estradiol receptors (ERs) [21]. ERs are of 3 subtypes; ER-α, ER-β and G-protein coupled receptor [22,23]. Although the structures of ER-α and ER-β are of similar nature, their tissue distributions and biological functions are different [24]. ER-α receptors were the only identified receptors until 1996. Estradiol depletion resulted in an imbalance in ER-α and ER-β expression [25]. The ER-β receptors in the kidney play an important role in improving renal performance [12]. ER-β have been localized in the smooth muscles of the renal blood vessels and have a crucial role in response to vascular injury in pre- and post-menopausal women [25]. Moreover, ER-β receptors have been linked to carcinogenesis and apoptosis of the renal tissue [21,26]. ER-β agonists were found to improve the activities of antioxidant enzymes in the renal tissue [27]. However, the involvement of ER-β in mediating E2 actions and its distribution in the renal tissue is still in need for more investigations.

A known modulator of the ERs is tamoxifen (TAM), which acts by binding to the ERs countering E2 effects on the cells [28]. This action favors its use in the treatment of hormone-dependent breast cancer [28]. Despite this important anticarcinogenic effect, TAM produces nephrotoxicity with overproduction of ROS and induction of oxidative stress [29]. The exact role of E2 therapy after TAM treatment for its protective effect against TAM-induced renal injury is not known. While the effects of TAM on kidney ER-α have been studied thoroughly [30], however, its effect on ER-β is still deficient in literature.

Estradiol administration in experimental OVX and TAM-induced nephrotoxicity provides an appropriate experimental model for studying the endocrine function, morphological and ultrastructural changes in the kidneys induced by menopause with the involvement of the ER-β receptors.

### Materials and methods

#### Chemicals

Estradiol was supplied as Folone ampoules 1 mL (Misr Co., for Pharm. ind. S.A.E. Cairo, Egypt). Each ampoule contains 5 mg estradiol benzoate. Estradiol was injected at a dose of 250 μg/kg/day, s.c. [31].

Tamoxifen (Sigma Chemical Co., St Louis, MO, USA) was suspended in 100 μL ethanol and dissolved in 900 μL corn oil. It was administered at a dose of 45 mg/kg/day intraperitoneally [30].

#### Experimental protocol

Sixty adult female Sprague–Dawley rats, 5 ± 0.4 weeks of age, weighing 165 ± 15 g each, were housed (Animal House, Medical Physiology department, Faculty of Medicine, Mansoura University, Egypt) in standard conditions under approved procedures by Medical Research Ethical Committee of Mansoura University, Egypt (IRB).

The rats were randomly assigned into six equal groups of 10 animals; one control group (Group I) and five OVX study groups. All remaining fifty rats were subjected for OVX under anesthesia (ketamine, 75 mg/kg, i.p. and xylazine, 10 mg/kg, i.p.) following the usual sterile surgical procedures [32].

#### Animal grouping and sample collection

The control group (group I) did not undergo any treatment. The remaining experimental 5 groups were further subdivided according to the treatment given after OVX. Group II received no treatment. After 2 weeks of OVX. Estradiol was given for 3 weeks in group III, TAM for 7 days in group IV and TAM (for 7 days) followed by E2 (for 3 weeks) in group V, and E2 (for 3 weeks) followed by TAM (for 7 days) in group VI. A schematic representation of the timing of drug treatments is illustrated in Figure 1.

At the end of the experimental periods, overnight fasted rats were anesthetized by pentobarbital (60 mg/kg). Blood samples were collected by puncture of rat tail artery with a 25-gauge needle and collected into two tubes: the first one contained EDTA and was centrifuged at 2,000 rpm(1000 g) for 1 min at 4°C to obtain plasma samples which were used for measurement of renin, PGE2 and E2. In the second tube, the blood sample was collected without anticoagulant to obtain serum for determination of serum creatinine (SCr), blood urea nitrogen (BUN) & serum vitamin D (SD).
The animals were sacrificed under the anesthesia and the kidneys were immediately excised from the dissected animals, trimmed of fats, and washed with physiological saline solution [33]. One excised kidney was used for the preparation of renal tissue homogenate by homogenizing 1 g of the kidney tissue in 10 mL potassium phosphate buffer containing 0.1 mM EDTA and centrifugation at 3000 rpm for 15 min.

**Assessment of kidney function biomarkers, oxidative stress parameters, and serum E2**

Serum creatinine was assessed using the Jaffépicric acid procedure, with Sigma kit 555-A # (Sigma–Aldrich Chemical Co.) [34]. Blood urea nitrogen was assessed by the enzymatic method (modified Berthelot reaction) (dp international; Tuscaloosa, USA) [35] and serum vitamin D (SD) was assessed using the ELISA [36].

Plasma renin (PR) was measured by an automated immunochemiluminometric assay [37]. Plasma Prostaglandin E2 (PGE2) was estimated by using titerzme PGE2 enzyme immunoassay kit, manufactured by Perspective Biosystems [38]. Estradiol was measured using an E2 DSL-4400 Radioimmunoassay kit (Diagnostic Systems Laboratories, Inc., Webster, TX, USA) according to the manufacturer’s instructions [39].

Renal erythropoitin (EPO) was determined from the homogenates by EPO ELISA kit [40]. The level of renal Malondialdehyde (MDA) as a marker of lipid peroxidation (LPO) [41] was determined by thiobarbituric acid 0.67% and trichloroacetic acid 10% method [42]. The activity of renal Glutathione Peroxidase (GPx) [43], Catalase (CAT) [44] and Superoxide Dismutase (SOD) were measured as previously described by Afrazeh et al. [45].

**Microscopic study**

The other excised kidney was divided longitudinally into 2 halves; one half was fixed in 10% formalin in water for one week, dehydrated in ascending grades of ethanol, cleared in xylol and embedded in paraffin. Paraffin sections (4–5 µm thick) were cut and stained with hematoxylin and eosin [46] and ERβ immune staining [47]. The sections were examined with an Olympus light microscope and photographed.

**Ultrastructural study**

The other half of the kidney was cut into 1 mm² pieces and were immediately dipped in 2.5% glutaraldehyde and kept in the refrigerator at 4 °C for 2 h and processed for examination with PEM-100 transmission electron microscope [48] at EM unit in Mansoura University.

**Morphometric study**

The area of immunopositivity of ER-β staining was measured under 400X magnification. The slides were digitized and saved as TIFF files. The results obtained from the images were analyzed on Intel® Core I3R built computer by using Video Test Morphology R software.
were, group I
ably from unintended hemorrhage. The final numbers
difference. The significance is acceptable at
test for multiple comparisons using the least significant
when compared to group V.

Moreover, there was a significant increase in group IV
in comparison to group II. Group V showed a significant
increase in comparison to group IV, at the same time, group V
showed a significant decrease in comparison with
group IV in comparison to group II. Wherever there was a significant
decrease in comparison to group IV.

Serum creatinine, BUN and MDA were significantly
increased in group II (OVX group) in comparison to the
control group (group I) (Table 1). As a result of E2
administration after OVX in group III, there was a signifi-
cant decrease in their levels in comparison to group II.
Wherever there was a significant increase of SCr and
BUN in group IV due to the effect of TAM after OVX in
comparison to group II whereas, E2 given before TAM
in group V caused a significant decrease in comparison to
group IV. At the same time, TAM administered before
E2 in group VI caused a significant decrease in compari-
sion to group V. The antioxidants (GPx, CAT and SOD)
were significantly decreased in group II in comparison
to group I. There was a significant increase in their lev-
els in group III in comparison to group II. In addition,
there was a significant decrease in antioxidants in
group IV in comparison to group II. Group V showed a
significant increase in comparison to group IV, at the
same time, CAT & SOD in group VI showed a significant
decrease in comparison to group V but no significant
change in GPx levels was reported.

Renal erythropoietin was significantly increased in
group II in comparison to group I. There was a signifi-
cant decrease in group III in comparison to group II.
Moreover, there was a significant increase in group IV
in comparison to group II, at the same time, group V
showed a significant decrease in comparison with
group IV but group VI showed no significant change
when compared to group V.

Statistical analysis
Data are expressed as mean ± standard deviation.
Statistical analysis was performed using statistical pack-
age for social science (SPSS software, version 22).
Significance between the different experimental groups
was determined by one-way ANOVA, followed post hoc
test for multiple comparisons using the least significant
difference. The significance is acceptable at p < 0.05.

Results
Assessment of kidney function biomarkers,
oxidative stress, antioxidants parameters and
s E2
Serum creatinine, BUN and MDA were significantly
increased in group II (OVX group) in comparison to the
control group (group I) (Table 1). As a result of E2
administration after OVX in group III, there was a signifi-
cant decrease in their levels in comparison to group II.
Wherever there was a significant increase of SCr and
BUN in group IV due to the effect of TAM after OVX in
comparison to group II whereas, E2 given before TAM
in group V caused a significant decrease in comparison to
group IV. At the same time, TAM administered before
E2 in group VI caused a significant decrease in compari-
sion to group V. The antioxidants (GPx, CAT and SOD)
were significantly decreased in group II in comparison
to group I. There was a significant increase in their lev-
els in group III in comparison to group II. In addition,
there was a significant decrease in antioxidants in
group IV in comparison to group II. Group V showed a
significant increase in comparison to group IV, at the
same time, CAT & SOD in group VI showed a significant
decrease in comparison to group V but no significant
change in GPx levels was reported.

Renal erythropoietin was significantly increased in
group II in comparison to group I. There was a signifi-
cant decrease in group III in comparison to group II.
Moreover, there was a significant increase in group IV
in comparison to group II, at the same time, group V
showed a significant decrease in comparison with
group IV but group VI showed no significant change
when compared to group V.

PR was significantly increased in group II in compari-
sion to group I. In group III, there was a significant
decrease in comparison to group II. A significant
increase in group IV in comparison to group II was
noted. No significant change when comparing group V
to group IV and group VI to group V was reported.

PGE2 was significantly increased in group II in compari-
sion to group I. In group III, there was also a signifi-
cant increase in comparison to group II. A significant
increase of PGE2 in group IV in comparison to group II
was recorded. Group V showed a significant increase as
a comparison with group IV, but group VI showed no
significant change in comparison to group V.

Serum vitamin D3 was significantly decreased in
group II in comparison to group I. Group III, had a sig-
nificant increase in comparison to group II. Wherever
there was a significant decrease in group IV in compari-
sion to group II. Group V showed a significant increase
in comparison with group IV, but group VI showed a
significant decrease in comparison to group V.

Plasma E2 level was significantly decreased in group
II in comparison to group I. Group III also showed a sig-
nificant increase in comparison to group II. There was a
significant increase in group IV in comparison to group II.
A significant increase in comparing group V to group
IV and group VI to group V was reported.

Light microscopy
Microscopic examinations of the control group revealed
normal renal corpuscles with typical proximal tubules
(PT) and distal tubules (DT) (Figure 2(a)). The sections
from group II showed apparent congested glomerular
capillaries and narrow Bowman’s space. The PT had
vacuolated cytoplasm with loss of the apical brush bor-
der in most of the lining cells. The DT had pale vacu-
culated cytoplasm with widened tubular cavities and
congested intervening vasculature (Figure 2(b)).
Estradiol-treated group III showed apparent normal
Bowman’s space with less evident congestion of the
glomerular capillaries. The PT retain the apical brush
border with few cytoplasmic vacuolations. The DT
appeared almost normal (Figure 2(c)). In group IV,
following TAM treatment showed seemingly narrow
Bowman’s space with segmented glomerulus and con-
gested capillaries. The PT and DT were more or less
similar to group II apart from the congested vasculature
(Figure 2(d)). Group V (E2 + TAM group) revealed appar-
ten dilated and congested glomerular capillaries. Some
of the cell lining of the PT lost the apical brush border
and had vacuolated cytoplasm. Few of the DT epithelial
cells had pale vacuolated cytoplasm with widened
cavities and congested blood vessels (Figure 2(e)). When TAM preceded E2 in group VI, glomeruli and PT were more or less similar to that of group II. The DT had a pale vacuolated cell lining with a widened cavity and precipitated eosinophilic cast in the lumen of some. Most of the outer cortical tubules appeared vacuolated (Figure 2(f)).

**Er-β immune staining**

Group I stained sections showed almost absent expression of the stain in the glomerular cells’ cytoplasm and complete lack of expression in the interstitial cells, PT and DT epithelial cells (Figure 3(a)). Group II showed moderate expression in the glomerular cells’ cytoplasm, little expression in some of the PT, interstitial cells, and no expression in the DT (Figure 3(b)). Group III had a weak expression in the glomerular cells’ cytoplasm, almost absent expression in the interstitial cells, PT and DT epithelial cells (Figure 3(c)). Group IV showed marked expression in the glomerular cells’ cytoplasm, PT, interstitial cells, and DT (Figure 3(d)). Group V showed moderate expression in the glomerulus’ cytoplasm, weak expressions in some of the PT, interstitial cells, and DT epithelial cells (Figure 3(e)). Group VI showed more expression of the Er-β antibody in relation to group V (Figure 3(f)).

Quantitative measurement of the area of immunopositivity showed significantly decreased in group II in comparison to group I. Group III, had a significant increase in comparison to group II. However, there was a significant decrease in group IV in comparison to group II. Group V showed a significant increase in comparison with group IV, but group VI showed a significant decrease in comparison to group V (Table 2).

**Electron microscopy**

Transmission electron microscopy of group I showed typical glomerular capillaries with uniform thickened basement membrane and typical lining cells of PT and DT (Figures. 4(a), 5(a) & 6(a)). Group II showed irregular thickening of the basement membrane of the glomeruli. The foot processes of the podocytes appeared irregularly distributed with abnormal spaced filtration slits (Figure 4(b)). The PT had retained some of the free border microvilli but had swollen mitochondria, numerous secondary lysosomes, cytoplasmic vacuoles and pyknotic nuclei (Figure 5(b)). The DT had elongated bizzare-shaped mitochondria and cytoplasmic vacuoles (Figure 6(b)). Group III showed almost typical glomeruli

### Table 1. Effect of ovariectomy, estradiol and tamoxifen on serum creatinine (Scr) (mg/dl), blood urea nitrogen (BUN; mg/dl), renal oxidative stress (MDA) antioxidants parameters (GPx, CAT, SOD), renal erythropoietin (EPO pg/ml), plasma renin (PR mU/L), plasma prostaglandine E2 (PGE2 pg/ml), serum vitamin D (SD pmol/l) and plasma 17 b-estradiol levels (E2 pg/ml) (mean ± SD).

| Parameters          | Group I (N = 10) | Group II (N = 9) | Group III (N = 9) | Group IV (N = 8) | Group V (N = 10) | Group VI (N = 9) |
|---------------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Scr (mg/dl)         | 0.4 ± 0.05      | 3.5 ± 0.21      | 1.7 ± 0.31      | 5.3 ± 0.14      | 3.4 ± 0.13      | 2.5 ± 0.14      |
| BUN (mg/dl)         | 36.3 ± 0.3      | 66.5 ± 1.3      | 70.34 ± 5.34    | 116.2 ± 9.51    | 100.34 ± 8.35   | 80.35 ± 7.31    |
| Renal MDA (nmol/g protein) | 63.4 ± 4.93 | 90.30 ± 5.34    | 70.34 ± 5.32    | 116.2 ± 9.51    | 100.34 ± 8.35   | 80.35 ± 7.31    |
| Renal GPx (U/L)     | 46.7 ± 3.11     | 30.34 ± 2.41    | 35.34 ± 3.46    | 19.2 ± 3.13     | 25.35 ± 2.87    | 22.35 ± 3.12    |
| Renal CAT (U/L)     | 34.6 ± 2.18     | 27.37 ± 1.85    | 30.37 ± 1.96    | 14.4 ± 1.83     | 24.35 ± 2.10    | 20.83 ± 2.31    |
| Renal SOD (U/L)     | 56.1 ± 2.56     | 30.24 ± 2.34    | 47.53 ± 2.76    | 22.1 ± 3.15     | 31.35 ± 3.52    | 27.20 ± 2.12    |
| Renal EPO (pg/ml)   | 44.3 ± 1.8      | 69.5 ± 1.7      | 26.7 ± 1.2      | 76.2 ± 1.0      | 40.8 ± 1.8      | 41.9 ± 1.1      |
| PR (mU/L)           | 200.5 ± 32.3    | 240.1 ± 18.3    | 101.3 ± 20.2    | 270.4 ± 13.8    | 225.5 ± 12.5    | 230.5 ± 35.2    |
| PGE2 (pg/ml)        | 357.23 ± 12.43  | 2073.42 ± 283.65| 2382.12 ± 127.21| 2794.76 ± 379.56| 2960.53 ± 132.41| 2890.34 ± 201.23|
| SD (pmol/l)         | 200.5 ± 32.3    | 101.3 ± 20.2    | 149.1 ± 18.3    | 80.4 ± 13.8     | 160.5 ± 12.5    | 85.5 ± 35.2     |
| PlasmaE2 (pg/ml)    | 35.5 ± 4.9      | 8.5 ± 1.4       | 20.8 ± 2.4      | 9.6 ± 1.2       | 21.3 ± 2.7      | 25.2 ± 2.4      |

*<p1*: statistical significance between control group I versus group II.
*<p2*: statistical significance between group II versus group III.
*<p3*: statistical significance between group II versus group IV.
*<p4*: statistical significance between group IV versus group V.
*<p5*: statistical significance between group V versus group VI.
Test of significance p < 0.05.

ns: Not significant; SD: Standard deviation.
The PT and DT had few cytoplasmic vacuoles (Figures 5(c) & 6(c)). Group IV had the glomerular capillaries packed with erythrocytes with areas of irregular thickening of the basement membrane and abnormal foot processes of the podocytes (Figure 4(d)). The PT had fewer microvilli, swollen mitochondria, numerous secondary lysosomes and cytoplasmic vacuoles (Figure 5(d)). DT showed irregular thick basal lamina with scarce bizzare-shaped mitochondria, cytoplasmic vacuoles, and pyknotic nuclei (Figure 6(d)). Group V glomeruli had few areas of irregular thickening of the basement membrane and abnormally distributed filtrum slits (Figure 6(e)). The PT had detached microvilli, elongated swollen mitochondria, secondary lysosomes and cytoplasmic vacuoles (Figure 5(e)). DT had apparent normal elongated mitochondria with some
Figure 3. Photomicrograph of Er-β immune stained paraffin sections showing almost absent expression of the stain in the cytoplasm of glomerular cells (arrow) in the control group (group I) (a), moderate expression in the cytoplasm of glomerular cells (arrows) in ovariectomized group (group II) (b) and group estradiol treated group (group V) (e), weak expression in the glomerular cells’ cytoplasm (arrow) in group estradiol treated group (group III) (c), marked expression in the glomerulus cells’ cytoplasm (arrows) in group tamoxifen treated group (group IV) (d) and group tamoxifen and estradiol treated group (group VI) (f). Complete absent expression of the stain in the interstitial cells and proximal convoluted tubules (P) in groups I and III, few expression in some of the interstitial cells (arrow heads) and PT (P) in groups II and V and few expression in some of the DT (D) in group V. Marked expression in the interstitial cells (arrow-heads), PT (P) and DT epithelial cells (D) in groups IV and VI and no expression in the DT (D) in groups I, II and III is noted.

Table 2. The Relative ER-β positive immuno-staining area expressed as the percentage of the total kidney sectional area, in ER-β immune stained sections. Data are the mean ± SD.

| Parameters                  | Group I N = 10 | Group II N = 9 | Group III N = 9 | Group IV N = 8 | Group V N = 10 | Group VI N = 9 |
|-----------------------------|----------------|----------------|-----------------|----------------|----------------|----------------|
| ER-β immune staining area (μm²) | 11.17 ± 0.32   | 14.31 ± 2.32   | 41.16 ± 5.72    | 23.54 ± 8.67   | 10.26 ± 4.47   | 21.12 ± 8.12   |

p1: statistical significance between control group I versus group II.
p2: statistical significance between group II versus group III.
p3: statistical significance between group II versus group IV.
p4: statistical significance between group IV versus group V.
p5: statistical significance between group V versus group VI.

Test of significance p < 0.05.
SD: Standard deviation.
cytoplasmic vacuoles (Figure 6(e)). Group VI glomerular capillaries, PT and DT are more or less close to that of group V (Figures 4(f), 5(f) & 6(f)).

**Discussion**

The endocrine functions of the kidney represent one of the important aspects of hormone physiology and pathology. Though, this subject does not seem to have received due attention in the literature [50]. Estradiol is a fundamental hormone in the maintenance of the functions of the renal tissue. It is feasible that the abrupt reduction in E2 levels by OVX can trigger complex functional and structural disturbances with consequent changes of excretory and endocrine functions of the kidney. Serum creatinine and BUN are measured as an index of renal function. A significant increase in their levels with variable values was in all the experimental groups following OVX. The highest increase in their levels was in group IV when compared with the group I. The increased level of SCr in group II (OVX alone group) can be explained either by increased SCr production by muscles as a result of absence of estrogen anabolic effect [51] or by the decrease SCr clearance by the

![Image of glomerular capillaries](image_url)
kidneys due to decreased renal perfusion and GFR induced by oxidative stress mediated by OVX [52].

At the same time, OVX significantly increased MDA and decreased GPx, CAT, and SOD. These findings of oxidative stress are accompanied by the morphological alteration in the form of glomerular hypertrophy and narrowing of the Bowman’s space with degenerative changes of the PT epithelial cells. The ultrastructural examination of the glomeruli showed areas of irregular thickening of the glomerular basement membrane with irregularly distributed abnormal filtrum slits of podocytes. PT cell lining showed numerous secondary lysosomes, cytoplasmic vacuoles and pyknotic nuclei. The increase in lysosomes was explained by the increased autophagic process and decreased activity of free ribosome, endoplasmic reticulum and Golgi apparatus secondary to oxidative stress [53].

The significant decrease in oxidative parameters was observed in E2 supplemented groups (III, V & VI). These results were in agreement with the observations made by Azarkish et al. [54]. Ovariectomy effects were explained by an increase in oxidative stress parameter (MDA) and decreased in the levels of antioxidants [55]. Estradiol supplementation alleviated this renal tissue stress through its effect on glomerular mesangial cells and the smooth muscles cells of blood vessels by activating the expression of anti-inflammatory cytokines and interleukine-6 [56]. Several previous studies have
attributed the protective effects of E2 to nitric oxide synthases system [57], antioxidant [58], and proinflammatory properties response [59].

Tamoxifen-induced nephrotoxicity was approved by the increase of BUN and SCr levels in group IV, when compared with group II. While this TAM-induced nephrotoxicity was not marked in E2-treated groups (III & V). The decreased level of SCr and BUN in group VI in comparison with group V can be explained by the blocking effect of ERs by TAM and increased TAM-induced PGE2 and EPO synthesis.

At the same time, TAM significantly increased the serum level of MDA and significantly decreased GPx, CAT, and SOD in groups IV & VI. The E2 antioxidant action was less notifiable in group VI, simply because the prior use of TAM minimized this effect. A less discernible effect was detected in group V when E2 was used before TAM.

In OVX females treated with TAM, E2 reversed the levels of MDA, GPx, CAT, and SOD. This can be explained by the ability of TAM or its metabolites to bind to the ERs masking its action and covalently bind to DNA leading to the formation of DNA adduct [30]. Tamoxifen induces oxidative stress and overproduction of ROS with an increase in lipid peroxidation which may be associated with TAM-induced release of iron ions which enhances the generation of hydroxyl radicals [29]. These changes cause renal vasoconstriction with altered glomerular filtration rate which may explain the observed increase in the kidney function biomarkers (SCr and BUN). The findings support the previous
observations that compounds with antioxidant properties as E2 can alleviate the TAM-induced nephrotoxicity was developed [60]. This could be further explained by our experience of administration of E2 in group III and V significantly improved the levels of BUN and SCr, elevated the antioxidant enzymes and attenuated the MDA. This result was explained by the fact that E2 inhibits lipid and protein oxidation, preserves membrane permeability, and reduces the level of hydroxyl radicals [29] by its polyphenolic compounds [61].

The extensive changes either in light microscopy or in the ultrastructural examination in groups IV and VI were attributed to vasoactive mediators induced by oxidative stress [29,49]. The protective effect of E2 was approved histopathologically by minimal glomerular, PT and DT changes when compared to the OVX rats. This is in agreement with the previous studies which reported the same findings and attributed the changes to the enhancement of cytoplasmic anabolism by substitution of E2 [53].

Ovariectomy induced a significant increase in EPO level in group II. This elevated level occurred secondary to its augmented production from interstitial cells of the renal cortex, near the base of the PT [4]. Tamoxifen increased EPO level in group IV by its EPO-stimulating ability of renal peritubular cells [62]. Group III and V showed significant change while group VI had a non-significant change. This effect was attributed to effects of E2 on EPO via inhibiting renal EPO gene expression which is mediated by increasing nitric oxide production [63,64]. Furthermore, EPO itself was found to act as an antioxidant and antiapoptotic agent and has a protective effect against OVX & TAM-induced nephrotoxicity [65].

Our results revealed that OVX induced a significant increase in PR that was more with TAM in groups IV. In accordance with our findings that OVX increased PR, some studies reported its increase post-menopause [66]. Reduction in E2 activates RAS and increases the expression of endothelin-1 which is a known vasoconstrictive agent that causes inflammation and oxidative stress with subsequent acute renal function impairment, associated with mesangial cell proliferation and inflammation [67]. By light microscopy, the macula densa appeared more deeply stained in TAM-treated group indicating its hyperactivity. Our results showed that PT retained the free border microvilli and production of angiotensin converting enzyme explaining the associated increase in MDA as a result of Ang II.

The elevation in the levels of PR due to TAM-induced toxicity can be explained by the decrease in the glomerular filtration rate. This finding is in concordance with Miller et al. [68]. Moreover, our results showed that E2 supplementation decreased PR in group III. This result was explained by Pasqualini et al. [69] suggesting that E2 increases angiotensin concentrations by increasing PR5 or by enhancing angiotensin synthesis. By negative feedback mechanism, Ang II might exert a direct renal inhibitory effect on renin release or indirect inhibition could result from the increased plasma volume as a result of the effect of Ang II and aldosterone on the DT [70]. Our results are in agreement with the hypothesis that E2 does not stimulate the synthesis and release of renin by the kidney [71]. The response to E2 is confirmed by the apparent normal appearance of the DT in the ultrastructural examination.

Our study revealed that OVX induced a significant increase of PGE2 that is more evident with the TAM (group VI). In addition to this, there was a significant increase of PGE2 in E2 treated groups (III & V).

Previous studies have demonstrated that the PGE2 formed by COX-2 in the renal cortex participates in the control of renin synthesis [9] and that its expression is regulated by dietary salt intake [72] and Ang II [73]. However, the effects of OVX on expression and function of renal COX-2 is still unclear. The present study revealed a significant increase of PGE2 as a result of OVX which aggravated further after administration of E2. This finding was explained by that OVX enhanced the expression of COX-2 in the interstitial cells adjacent to the macula densa through proinflammatory mediators and oxidative stress mechanisms that is independent to salt intake. This was associated with increased urinary excretion of PGE2 in rats [74]. Therefore, E2-dependent COX-2 expression plays an important role in the regulation of PGE2 level and the changes produced by it in regards to renal blood flow and the protective mechanisms in kidneys against various stress conditions. A study by Pedram et al. [73], revealed that the COX-2 promoter gene contains an E2-binding site suggesting that E2 may directly affect the expression of the COX-2.

Our results showed a significant increase in PGE2 by E2 (groups III, V, VI). This is corresponding with the previous studies which demonstrated that E2 influence renal COX-2 through stimulation of the nitric oxide systems by up-regulation of neuronal nitric oxide synthesis [75]. A study by Armando et al. [76] showed that E2 up-regulates renal Ang II type 2 receptors which antagonize the inhibitory effect of Ang II type 1 receptors on Ang II synthesis that stimulates renal COX-2 expression increasing PGE2 [77]. TAM-induced PGE2 increase can be attributed to the direct stimulatory effect of TAM on COX2 expression [78]. Ovariectomy involves both mediators; nitric oxide and Ang II in the up-regulation of renal COX-2.

Our data showed that there was a significant decrease in SD in OVX group (II) and TAM-treated
groups (IV & VI) and a significant increase in SD in E2 treated groups (III &V). The mitochondria of cell lining of PT of groups II and IV appeared swollen and bizarre shaped which might cause the decrease SD level in these groups. Estradiol administration changed the mitochondrial shape in the PT of group III and V to become longitudinal and mildly swollen. It is observed that TAM decreases the synthesis of the SD via inhibition of expression of 1-hydroxylase enzyme [79], hence vitamin D3 supplementation is advised during treatment of breast cancer by TAM to compensate for its deficiency and antiproliferative effects.

In the present study, the level of plasma estradiol was measured to monitor E2 levels during the experimental study. As E2 and TAM actions are mediated by ERs, ER-β stain was used to demonstrate this action. Our results showed a progressive increase in ER-β stain expression in the absence of E2 (groups II, IV and VI). On the other hand, a restoration of the weak expression accompanied E2 supplementation (groups III and V). The dynamic balance between ER-β and ER-α is important to mediate the proper E2 action [25,80]. The ER-β has been shown to be specifically important in the inflammatory response to OVX [81]. The E2 signaling of ER-β has a protective effect on the renal tissue by mediating vascular relaxation [56]. The increase in ER-β occurs as an up-regulation mechanism as reported in previous studies [25]. On the contrary, Rogers et al. [82] reported that there is no effect of OVX on ER-β expression. This dissociation was explained by possible genetic differences in the animal strains used [25].

Our study showed that E2 replacement ameliorated TAM-induced nephrotoxicity and oxidative stress. The improvement of renal function and structural changes was explained by E2 membrane signaling through binding to ER receptors initiating transcriptional regulation of the cell function [23]. A better understanding of ERs-E2 signaling pathway is in need of immense investigations.

**Conclusion**

The present study supports the concept that E2 has a protective effect against renal structural changes and endocrine dysfunctions induced by OVX and/or TAM. The depletion of the renal redox system together with the liberation of free radicals in response to E2 deficiency or TAM is blamed for the accompanying renal injury. Estradiol improves TAM-induced renal injury possibly by its antioxidant properties. ER-β plays an important role in mediating the actions of E2 and its antagonists. Further investigations are needed to disclose the knowledge about the expression level of ERs and their exact role in mediating E2 and TAM actions.

**Disclosure statement**

All authors declare no conflicts of interest.

**References**

[1] Sahay M, Kalra S, Bandgar T. Renal endocrinology: the new frontier. Indian J Endocr Metab. 2012;16:154–155.
[2] Castrop H, Hocherl K, Kurtz A, et al. Physiology of kidney renin. Physiol Rev. 2010;90:607–673.
[3] Li XC, Zhuo JL. Recent updates on the proximal tubule renin-angiotensin system in angiotensin II-dependent hypertension. Curr Hypertens Rep. 2016;18:63.
[4] Souma T, Nezu M, Nakano D, et al. Erthropoietin synthesis in renal myofibroblasts is restored by activation of hypoxia signaling. J Am Soc Nephrol. 2016;27:428–438.
[5] Hirata M, Endo K, Ohkawa H, et al. A comparison between daily and twice-weekly i.v. administration of 1,25-dihydroxy-22-oxavitamin D3 regarding suppression of parathyroid hormone secretion and calcemic action in uremic rats. Nephrol Dial Transplant. 2002; 17:37–40.
[6] Santoro D, Caccamo D, Lucisano S, et al. Interplay of vitamin D, erthropoiesis, and the renin-angiotensin system. Biomed Res Int. 2015;2015:145828.
[7] Kohan DE, Inacho EW, Wesson D, et al. Physiology of endothelin and the kidney. Compr Physiol. 2011;1:883–919.
[8] Williams CS, DuBois RN. Prostaglandin endoperoxide synthase: why two isoforms? Am J Physiol. 1996;270:G393–G400.
[9] Ichihara A, Imig JD, Inacho EW, et al. Cyclooxygenase-2 participates in tubular flow-dependent afferent arteriolar tone: interaction with neuronal NOS. Am J Physiol. 1998;275:F605–F612.
[10] Lichtnekert J, Kaverina NV, Eng DG, et al. Renin-angiotensin-aldosterone system inhibition increases podocyte derivation from cells of renin lineage. J Am Soc Nephrol. 2016;27:3611–3627.
[11] Morel F, Imbert-Teboul M, Chabardes D. Receptors to vasopressin and other hormones in the mammalian kidney. Kidney Int. 1987;31:512–520.
[12] Lee HR, Kim TH, Choi KC. Functions and physiological roles of two types of estrogen receptors, ERalpha and ERbeta, identified by estrogen receptor knockout mouse. Lab Anim Res. 2012;28:71–76.
[13] Uemura H, Irahara M, Yoneda N, et al. Close correlation between estrogen treatment and renal phosphate reabsorption capacity. J Clin Endocrinol Metab. 2000;85:1215–1219.
[14] Neugarten J, Acharya A, Silbiger SR. Effect of gender on the progression of nondiabetic renal disease: a meta-analysis. J Am Soc Nephrol. 2000;11:319–329.
[15] Gluhovschi G, Gluhovschi A, Anastasiu D, et al. Chronic kidney disease and the involvement of estrogen hormones in its pathogenesis and progression. Rom J Intern Med. 2012;50:135–144.
Diel P, Laudenbach-Leschowsky U, Friedel A, et al. 

Kim D, Lee AS, Jung YJ, et al. Tamoxifen ameliorates 

Tabassum H, Parvez S, Rehman H, et al. Tamoxifen-2-hydroxyl- 

Shukla J, Sharma U, Kar R, et al. Tamoxifen-2-hydroxyl- 

Kumral ZN, Memi G, Ercan F, et al. Estrogen alleviates 

Yang M, Liu B, Jin L, et al. Estrogen receptor beta 

Esqueda ME, Craig T, Hinojosa-Laborde C. Effect of 

Menazza S, Murphy E. The expanding complexity of 

Speirs V, Skliris GP, Burdall SE, et al. Distinct expression 

Esqueda ME, Craig T, Hinojosa-Laborde C. Effect of 

Yang M, Liu B, Jin L, et al. Estrogen receptor beta 

Kumral ZN, Memi G, Ercan F, et al. Estrogen alleviates 

Shukla J, Sharma U, Kar R, et al. Tamoxifen-2-hydroxyl- 

Tabassum H, Parvez S, Rehman H, et al. Nephrotoxicity and its prevention by taurine in ovariectomised rats. Mol Cell Endocrinol. 2005;230:7–15.

Flores A, Gallegos Al, Velasco J, et al. The acute effects of bilateral ovariectomy or adrenalectomy on progesterone, testosterone and estradiol serum levels depend on the surgical approach and the day of the estrous cycle when they are performed. Reprod Biol Endocrinol. 2008;6:48.

Pezeshki Z, Nematabakhsh M, Mazahei S, et al. Estrogen abolishes protective effect of erythropoietin against cisplatin-induced nephrotoxicity in ovariectomized rats. ISRN Oncol. 2012;2012:890310.

Delanghe JR, Speeckaert MM. Creatinine determination according to Jaffe—what does it stand for? NDTplus. 2011;4:83–86.

Venes DA, Cheung C, Pat B, et al. Erythropoietin protects against ischaemic acute renal injury. Nephrol Dial Transplant. 2004;19:348–355.

Close GL, Russell J, Cobley JN, et al. Assessment of vitamin D concentration in non-supplemented professional athletes and healthy adults during the winter months in the UK: implications for skeletal muscle function. J Sports Sci. 2013;31:344–353.

Sealey JE. Plasma renin activity and plasma prorenin assays. Clin Chem. 1991;37:1811–1819.

Tada Y, Ichihara A, Koura Y, et al. Ovariectomy enhances renal cortical expression and function of cyclooxygenase-2. Kidney Int. 2004;66:1966–1976.

Mohamed MK, Abdel-Rahman AA. Effect of long-term ovariectomy and estrogen replacement on the expression of estrogen receptor gene in female rats. Eur J Endocrinol. 2000;142:307–314.

Matsumura Y, Ikegawa R, Tsukahara Y, et al. Conversion of big endothelin-1 to endothelin-1 by two types of metalloproteinases derived from porcine aortic endothelial cells. FEBS Lett. 1990;272:166–170.

Brzovic-Saric V, Landeka I, Saric B, et al. Levels of selected oxidative stress markers in the vitreous and serum of diabetic retinopathy patients. Mol Vis. 2015;21:649–664.

Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem. 1979;95:351–358.

Paglia DE, Valentine WN. Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med. 1967;70:158–169.

Vitai M, Goth L. Reference ranges of normal blood urea nitrogen and creatinine according to Jaffe—what does it stand for? NDTplus. 2011;4:86.

Banchroft J. Theory and practice of histological techniques. 4th ed. London: Churchill Livingstone; 1996.

Taylor AH, Al-Zawawi F. Immunolocalisation of oestrogen receptor beta in human tissues. J Mol Endocrinol. 2000;24:145–155.

Elsayed WM, Mohamed HA. Dietary zinc modifies diabetic-induced renal pathology in rats. Ren Fail. 2017;39:246–257.

Eladl MA, Elsaed M, Atef H, et al. Ultrastructural changes and nestin expression accompanying compensatory renal growth after unilateral nephrectomy.
in adult rats. Int J Nephrol Renovasc Dis. 2017;10: 61–76.

[50] Sahay M, Kalra S, Bandgar T. Renal endocrinology: the new frontier. Indian J Endocrinol Metab. 2012;16: 154–155.

[51] Christy NP, Shaver JC. Estrogens and the kidney. Kidney Int. 1974;6:366–376.

[52] Ratliff BB, Abdulmahdi W, Pawar R, et al. Oxidant mechanisms in renal injury and disease. Antioxid Redox Signal. 2016;25:119–146.

[53] Schiebler TH, Danner GK. The effect of sex hormones on the proximal tubule of the rat kidney. Acta Med Pol. 1979;20:453–454.

[54] Azarkish F, Nematzakhsh M, Fazilati M, et al. N-acetyl-cysteine prevents kidney and lung disturbances in renal ischemia/reperfusion injury in rat. Int J Prev Med. 2013;4:1139–1146.

[55] Kucuk A, Kabadere S, Tosun M, et al. Protective effects of doxycycline in ischemia/reperfusion injury on kidney. J Physiol Biochem. 2009;65:183–191.

[56] Dubey RK, Jackson EK. Estrogen-induced cardiorenal protection: potential cellular, biochemical, and molecular mechanisms. Am J Physiol Renal Physiol. 2001;280:F365–F388.

[57] Satake A, Takaoka M, Nishikawa M, et al. Protective effect of 17beta-estradiol on ischemic acute renal failure through the PI3K/Akt/eNOS pathway. Kidney Int. 2008;73:308–317.

[58] Mooradian AD. Antioxidant properties of steroids. J Steroid Biochem Mol Biol. 1993;45:509–511.

[59] Josefsson E, Tarkowski A, Caristen H. Anti-inflammatory properties of estrogen. I. In vivo suppression of leukocyte production in bone marrow and redistribution of peripheral blood neutrophils. Cell Immunol. 1992;142:67–78.

[60] Berlett BS, Stadtman ER. Protein oxidation in aging, disease, and oxidative stress. J Biol Chem. 1997;272: 20313–20316.

[61] Skrzydlewska E, Ostrowska J, Farbiszewski R, et al. Protective effect of green tea against lipid peroxidation in the rat liver, blood serum and the brain. Phytomedicine. 2002;9:232–238.

[62] Asada N, Takase M, Nakamura J, et al. Dysfunction of fibroblasts of extrarenal origin underlies renal fibrosis and renal anemia in mice. J Clin Invest. 2011;121: 3981–3990.

[63] Wise PM, Dubal DB. Estradiol protects against ischemic brain injury in middle-aged rats. Biol Reprod. 2000;63:982–985.

[64] Kalu DN, Salerno E, Liu CC, et al. A comparative study of the actions of tamoxifen, estrogen and progesterone in the ovariectomized rat. Bone Miner. 1991;15: 109–123.

[65] Pezeshki Z, Nematzakhsh M, Nasri H, et al. Evidence against protective role of sex hormone estrogen in Cisplatin-induced nephrotoxicity in ovariectomized rat model. Toxicol Int. 2013;20:43–47.

[66] Schunkert H, Danser AH, Hense HW, et al. Effects of estrogen replacement therapy on the reinit of the non-genomic and genomic actions of estrogen. Membrane-initiated signaling by steroid to transcription and cell biology. J Biol Chem. 2002;277: 50768–50775.

[67] Tang J, Yan H, Zhuang S. Inflammation and oxidative stress in obesity-related glomerulopathy. Int J Nephrol. 2012;2012:1.

[68] Miller RP, Tadagavadi RK, Ramesh G, et al. Mechanisms of Cisplatin nephrotoxicity. Toxins (Basel). 2010;2:2490–2518.

[69] Pasqualini C, Leviel V, Guibert B, et al. Inhibitory actions of acute estradiol treatment on the activity and quantity of tyrosine hydroxylase in the median eminence of ovariectomized rats. J Neuroendocrinol. 1991;3:575–580.

[70] Gebara OC, Mittleman MA, Sutherland P, et al. Association between increased estrogen status and increased fibrinolytic potential in the Framingham Offspring Study. Circulation. 1995;91:1952–1958.

[71] Birkenfeld A, Kase NG. Menopause medicine: current treatment options and trends. Compr Ther. 1991;17: 36–45.

[72] Yang T, Singh I, Pham H, et al. Regulation of cyclooxygenase expression in the kidney by dietary salt intake. Am J Physiol. 1998;274:F481–F489.

[73] Pedram A, Razandi M, Aitkenhead M, et al. Integration of the non-genomic and genomic actions of estrogen. J Clin Invest. 2012;2012:1.

[74] Dillon MF, Stafford AT, Kelly G, et al. Cyclooxygenase-2 predicts adverse effects of tamoxifen: a possible mechanism of role for nuclear HER2 in breast cancer patients. Endocr Relat Cancer. 2008;15:745–753.

[75] Dusso A, Arcidiacono MV, Yang J, et al. Vitamin D inhibition of TACE and prevention of renal osteodystrophy and cardiovascular mortality. J Steroid Biochem Mol Biol. 2010;121:193–198.

[76] Pare G, Krust A, Karas RH, et al. Estrogen receptor-alpha mediates the protective effects of estrogen against vascular injury. Circ Res. 2002;90:1087–1092.

[77] Bakir S, Mori T, Durand J, et al. Estrogen-induced vasoprotection is estrogen receptor dependent: evidence from the balloon-injured rat carotid artery model. Circulation. 2000;101:2342–2344.

[78] Rogers JL, Mitchell AR, Maric C, et al. Effect of sex hormones on renal estrogen and angiotensin type 1 receptors in female and male rats. Am J Physiol Regul Integr Comp Physiol. 2007;292:R794–R799.